Amylyx Pharmaceuticals Inc. [AMLX] Revenue clocked in at $0.30 million, up 49.58% YTD: What’s Next?

Amylyx Pharmaceuticals Inc. [NASDAQ: AMLX] gained 51.01% or 9.13 points to close at $27.03 with a heavy trading volume of 13064985 shares. The company report on September 7, 2022 that Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


– FDA Advisory Committee voted 7:2 that the available evidence of effectiveness is sufficient to support approval of AMX0035 for the treatment of ALS.

– If approved, AMX0035 will be the first treatment in ALS that has demonstrated a significant slowing of disease progression and functional decline, as well as extended survival, in a randomized, placebo-controlled clinical trial, as a standalone therapy or when added to existing approved treatments.

It opened the trading session at $31.30, the shares rose to $32.80 and dropped to $27.00, the range by which the price of stock traded the whole day. The daily chart for AMLX points out that the company has recorded 0.11% gains over the past six months. However, it is still -315.21% lower than its most recent low trading price.

If we look at the average trading volume of 873.85K shares, AMLX reached to a volume of 13064985 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Amylyx Pharmaceuticals Inc. [AMLX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AMLX shares is $30.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AMLX stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Citigroup have made an estimate for Amylyx Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 25, 2022. While these analysts kept the previous recommendation, Goldman dropped their target price from $36 to $10. The new note on the price target was released on April 01, 2022, representing the official price target for Amylyx Pharmaceuticals Inc. stock.

The Average True Range (ATR) for Amylyx Pharmaceuticals Inc. is set at 3.11, with the Price to Sales ratio for AMLX stock in the period of the last 12 months amounting to 6866.52. The Price to Book ratio for the last quarter was 8.17, with the Price to Cash per share for the same quarter was set at 2.71.

Trading performance analysis for AMLX stock

Amylyx Pharmaceuticals Inc. [AMLX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.09. With this latest performance, AMLX shares gained by 6.00% in over the last four-week period, additionally plugging by 0.11% over the last 6 months.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AMLX stock in for the last two-week period is set at 58.31, with the RSI for the last a single of trading hit 61.00, and the three-weeks RSI is set at 57.57 for Amylyx Pharmaceuticals Inc. [AMLX]. The present Moving Average for the last 50 days of trading for this stock 23.29, while it was recorded at 20.74 for the last single week of trading.

Amylyx Pharmaceuticals Inc. [AMLX]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Amylyx Pharmaceuticals Inc. [AMLX] shares currently have an operating margin of -29013.33 and a Gross Margin at +81.75. Amylyx Pharmaceuticals Inc.’s Net Margin is presently recorded at -30852.98.

Return on Equity for this stock declined to -188.05, with Return on Assets sitting at -146.90.

Amylyx Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.00 and a Current Ratio set at 8.00.

An analysis of insider ownership at Amylyx Pharmaceuticals Inc. [AMLX]

There are presently around $720 million, or 55.70% of AMLX stock, in the hands of institutional investors. The top three institutional holders of AMLX stocks are: VIKING GLOBAL INVESTORS LP with ownership of 7,170,536, which is approximately 0% of the company’s market cap and around 9.90% of the total institutional ownership; PERCEPTIVE ADVISORS LLC, holding 3,540,408 shares of the stock with an approximate value of $95.7 million in AMLX stocks shares; and BOXER CAPITAL, LLC, currently with $59.47 million in AMLX stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Amylyx Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 55 institutional holders increased their position in Amylyx Pharmaceuticals Inc. [NASDAQ:AMLX] by around 4,889,771 shares. Additionally, 26 investors decreased positions by around 1,686,746 shares, while 10 investors held positions by with 20,045,796 shares. The mentioned changes placed institutional holdings at 26,622,313 shares, according to the latest SEC report filing. AMLX stock had 20 new institutional investments in for a total of 819,192 shares, while 13 institutional investors sold positions of 589,410 shares during the same period.


Please enter your comment!
Please enter your name here